Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 14, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Clindamycin HydrochlorideCapsules USP, 75 mg, 150 mg, and 300 mg".
Press Release Mar 14 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Mar 09 2023
- Press Release Feb 17 2023
- Press Release Jan 23 2023
- Press Release Jan 17 2023
- Press Release Jan 10 2023
Later from Glenmark Pharmaceuticals
- Press Release Mar 16 2023
- Glenmark Pharmaceuticals Limited Press Release Mar 20 2023
- Glenmark Pharmaceuticals Limited Press Release Mar 23 2023
- Press Release May 19 2023
- Press Release Aug 01 2023
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals